Subscribe To Our Newsletter
Subscribe To Our Newsletter
A new nationwide class action lawsuit claims that Kourtney Kardashian Barker’s supplement brand, Lemme, uses deceptive marketing to sell its weight loss capsules, falsely advertising the product as a natural alternative to blockbuster prescription medications like Ozempic.
The lawsuit, filed in a California court on July 13, 2026, alleges that Lemme Inc. violated state consumer protection laws by advertising that its “Lemme GLP-1 Daily” capsules provide “un-hunger” and weight management benefits. According to the 23-page legal complaint, the company leveraged widespread public interest in pharmaceutical weight loss options to push a blend of lemon, orange, and saffron extracts that clinical science demonstrates does not actually reduce caloric intake or promote fat loss.
The legal action targets the marketing machine behind Lemme, a wellness brand co-founded by reality television star Kourtney Kardashian Barker and businessman Simon Huck. The lawsuit focuses on the company’s promotional campaign for Lemme GLP-1 Daily, a dietary supplement retailing for $90 for a single month’s supply, or up to $378 for a six-month subscription. The product has since been rebranded by the company as “Lemme Reset,” though it maintains the exact same formulation.
According to court documents, the brand’s marketing materials explicitly promised consumers that they would experience significant appetite control and fat reduction by taking the capsule twice a day. The brand touted the product as a “groundbreaking natural GLP-1 solution with no known side effects,” promising that users would see the “best results” if they used the capsules consistently for three to six months.
Plaintiffs argue that these aggressive marketing claims were intentionally designed to cash in on the current cultural craze surrounding prescription weight loss medications. By branding the supplement with the term “GLP-1,” the company allegedly led reasonable consumers to believe they were purchasing an over-the-counter equivalent to prescription injectables, despite lacking the necessary scientific testing to back up those performance claims.
At the center of the litigation is how glucagon-like peptide-1 (GLP-1) actually functions inside the human body. GLP-1 is a natural hormone produced in the small intestine that signals feelings of fullness, or satiety, to the brain while slowing down stomach emptying. The lawsuit explains that prescription medications, known as GLP-1 agonists, are specifically engineered in laboratories to mimic this hormone, remaining stable in the bloodstream for days to help manage obesity and Type 2 diabetes.
Lemme’s marketing materials told consumers that its plant-based capsules were clinically proven to increase the body’s naturally occurring GLP-1 levels by 17 percent. To support this claim, the company pointed to clinical studies conducted on one of its trademarked ingredients, a lemon extract called Eriomin.
However, the lawsuit points out a massive contradiction in the company’s scientific backing. The specific clinical study cited by Lemme actually demonstrated that the total calories consumed by human participants taking the lemon extract did not change at all throughout the entire duration of the research. Plaintiffs assert that the company completely omitted this crucial detail from its promotional campaigns, misleading everyday people into believing a minor chemical fluctuation would automatically translate into noticeable weight reduction.
The legal complaint goes into strict biological detail to explain why an over-the-counter fruit extract capsule cannot mimic a medical weight loss drug. In its natural state, the GLP-1 hormone produced by the human body is highly volatile. It is rapidly broken down by internal enzymes and possesses a functional half-life of a mere one to two minutes before disappearing from the system entirely.
By comparison, blockbuster prescription injectables containing semaglutide are structurally altered to resist enzyme breakdown. This engineering allows the synthetic hormone concentration in a patient’s blood to remain active for approximately seven days. The lawsuit notes that a standard weekly dose of a prescription drug results in a blood concentration that is 300,000% to 600,000% greater than the body’s resting level of natural GLP-1.
Because natural GLP-1 dissolves almost instantly, the lawsuit argues that a temporary 17 percent boost from a dietary supplement is biologically negligible. The complaint asserts that if weight loss were as simple as consuming basic citrus extracts, major pharmaceutical entities would not have spent decades and billions of dollars developing stable synthetic analogs to prevent rapid breakdown.
Beyond the biological disputes, the lawsuit accuses Lemme of using manipulative advertising tactics that directly targeted consumer anxieties. Court documents feature documented examples of the company’s social media and digital marketing campaigns across platforms like Instagram and Facebook. The plaintiffs allege that Lemme frequently highlighted the negative side effects and extreme financial costs associated with synthetic prescription medications to position its own product as a safer, cheaper alternative.
A standard prescription for a weight loss injection can cost upwards of $1,000 per month without comprehensive insurance coverage, leaving many desperate consumers priced out of the market. The lawsuit argues that Lemme intentionally exploited this economic barrier, offering its $90 bottle as a accessible substitute.
The plaintiff in the case, a consumer who purchased the capsules hoping to manage her weight, stated that she closely followed the company’s instructions but ultimately gained five pounds while taking the supplement. The lawsuit argues that if consumers had known the clinical studies behind the product showed zero reduction in actual caloric intake, they would have declined to purchase the capsules or refused to pay a premium price for them.
When a brand uses selective data to promote a dietary product, state and federal laws provide a framework to protect consumers from deceptive business practices. The current class action alleges that Lemme’s corporate practices constitute clear violations of three major pieces of California legislation:
The False Advertising Law (FAL): This statute makes it illegal for any business to distribute statements concerning property or services that are untrue or misleading, and which are known, or should be known, to be deceptive.
The Unfair Competition Law (UCL): This act prohibits any unlawful, unfair, or fraudulent business act or practice, protecting consumers from deceptive corporate behavior.
The Consumers Legal Remedies Act (CLRA): This law shields buyers against unfair methods of competition and deceptive practices, including representing that goods have ingredients, uses, or benefits that they do not have.
The legal team representing the plaintiffs argues that under these laws, a company cannot mount an “establishment claim”—stating that a product is clinically proven to offer a benefit—if the underlying clinical study flatly disproves the core marketing message. Because Lemme’s labels prominently promised weight management, the failure of the cited study to show a drop in caloric intake forms the cornerstone of the legal violation.
If you spent your hard-earned money on this supplement expecting to see clinical weight loss results, you don’t stand alone. The proposed class action lawsuit seeks to represent a nationwide class of everyday consumers, alongside a specific subclass of California residents, who bought the product during the legally applicable timeframe.
You may be eligible to participate in this class action investigation if you purchased:
Lemme GLP-1 Daily Capsules
Lemme Reset Capsules (the rebranded version of the exact same formula)
The product directly through the official website at LemmeLive.com or from authorized third-party retail channels for personal, household consumption.
It is important to note that this is not the first time Lemme has faced legal scrutiny over this specific product line. A separate class action lawsuit filed previously—Robbins v. Lemme—raised identical deceptive marketing allegations before ending in a voluntary dismissal with prejudice. Legal experts note that this historical outcome typically indicates that the parties reached an individual private settlement. Because the company is facing repeat litigation on the exact same core product, consumer advocacy attorneys are continuing to push for a broader resolution that provides direct restitution to all affected buyers.
New cases and investigations, settlement deadlines, and news straight to your inbox.
